dc.contributor.author |
Szebeni, János |
|
dc.contributor.author |
Bedőcs, Péter |
|
dc.contributor.author |
Urbanics R |
|
dc.contributor.author |
Bünger R |
|
dc.contributor.author |
Rosivall, László |
|
dc.contributor.author |
Tóth, Miklós |
|
dc.contributor.author |
Barenholz Y |
|
dc.date.accessioned |
2017-01-12T14:38:46Z |
|
dc.date.available |
2017-01-12T14:38:46Z |
|
dc.date.issued |
2012 |
|
dc.identifier |
84861669650 |
|
dc.identifier.citation |
pagination=382-387;
journalVolume=160;
journalIssueNumber=2;
journalTitle=JOURNAL OF CONTROLLED RELEASE; |
|
dc.identifier.uri |
http://repo.lib.semmelweis.hu//handle/123456789/3927 |
|
dc.identifier.uri |
doi:10.1016/j.jconrel.2012.02.029 |
|
dc.description.abstract |
PEGylated liposomal doxorubicin (Doxil) has been used in cancer chemotherapy for 16 years. Clinical experience shows that it can cause mild-to-severe hypersensitivity (infusion) reactions, which are manifestations of complement (C) activation-related pseudoallergy (CARPA). Although in most cases CARPA is inconsequential, a main symptom, cardiopulmonary distress, may be life threatening in hypersensitive individuals. To date, the prevention of Doxil-induced CARPA is based on premedication and a slow infusion protocol. The present study suggests desensitization by Doxil-like empty liposomes, called placebo Doxil (Doxebo), as an alternative strategy, which is based on the tachyphylactic nature of Doxil reactions. Doxebo-induced tolerance to Doxil was shown to develop within minutes and to be specific to Doxil-like PEGylated liposomes. The procedure of desensitization involves slow, low-dose pre-infusion of Doxebo before Doxil treatment which minimizes the ensuing physiological changes or keeps them subclinical. Although the mechanism of tolerance induction is not yet clear, the effector arm of C response is unlikely to be affected, as the vascular reactivity of desensitized pigs to zymosan remains intact. Desensitization with empty vesicles represents a novel approach for reducing the risk of anaphylactic reactions to drug carrier liposomes. The underlying immediate, most likely passive silencing of an innate immune response may represent a novel mechanism of tolerance induction which may work for other reactogenic nanosystems as well. © 2012 Elsevier B.V. |
|
dc.relation.ispartof |
urn:issn:0168-3659 |
|
dc.title |
Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: A porcine model |
|
dc.type |
Journal Article |
|
dc.date.updated |
2016-12-09T10:51:24Z |
|
dc.language.rfc3066 |
en |
|
dc.identifier.mtmt |
2005442 |
|
dc.identifier.wos |
000305788800034 |
|
dc.identifier.pubmed |
22421426 |
|
dc.contributor.department |
SE/AOK/K/ISZGYK/MTA-SE Gyermekgyógyászati és Nephrológiai Kutatócsoport |
|
dc.contributor.department |
SE/AOK/I/Kórélettani Intézet |
|
dc.contributor.department |
SE/Testnevelési és Sporttudományi Kar [2014.08.31] |
|
dc.contributor.department |
SE/KSZE/Nanomedicina Kutatási és Oktatási Központ |
|
dc.contributor.institution |
Semmelweis Egyetem |
|